跳至主要内容
临床试验/NCT04006886
NCT04006886已完成不适用

Gluten-free Diet in Patients With Primary Sclerosing Cholangitis (PSC) - a Pilot-Study

Universitätsklinikum Hamburg-Eppendorf2 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2017年7月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
17
试验地点
2
主要终点
Reduction of intestinal inflammatory activity

研究概览

简要总结

Gluten is a protein found in wheat and other cereals as barley and rye. It triggers an inflammatory reaction in the small-bowel of genetically predisposed persons. Alpha-amylase/trypsin inhibitors (ATIs) of wheat seem to be the responsible trigger of this intestinal Inflammation.

Intestinal inflammation is connected to other extra-intestinal autoimmune inflammations like PSC (as f.ex. the association of PSC with inflammatory bowel disease proves).

Hypothesis: Avoidance of ATIs through a gluten-free diet will reduce intestinal inflammation and thus also the the inflammatory activity in the liver.

Proof of hypothesis:

  • Pilot study with n=20 patients with PSC
  • Explorative, open-label, mono-centric study
  • Inclusion criteria: age 18-65, diagnosed PSC-associated colitis without relevant clinical activity after last coloscopy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • diagnosed PSC-associated colitis without relevant clinical activity after last coloscopy.

排除标准

  • patients with coeliac disease or wheat allergy
  • patients with active colitis
  • patients already on gluten-free diet
  • liver transplanted patients
  • patients also diagnosed with autoimmune hepatites (PSC-AIH overlap)
  • coloscopy within 2 months before study
  • Endoscopic retrograde cholangiopancreatography (ERCP) within 3 months before study
  • antibiotics within 3 month before study

结局指标

主要结局

Reduction of intestinal inflammatory activity

时间窗: 2 months

Expression of pro-inflammatory cytokines in gut mucosa (Sigma)

次要结局

  • Changes in patients microbiota(2 months (5 months with follow-up))
  • Inflammatory activity of the liver(2 months)
  • Reduction of inflammatory cells/markers in the blood(2 months)
  • Quality of life(2 months)
  • Change of symptoms with change of diet.(2 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Marcus Tetzlaff

study coordinator

Universitätsklinikum Hamburg-Eppendorf

研究点 (2)

Loading locations...

相似试验